Skip to main content

TGA receives application for an increased dose of GlaxoSmithKline’s COVID-19 treatment sotrovimab (XEVUDY) for the BA.2 Omicron sublineage

The TGA has received an application from GlaxoSmithKline (GSK) Australia Pty Ltd for a higher (1000 mg) dose of its COVID‑19 treatment, sotrovimab (XEVUDY)

Related content

Help us improve the Therapeutic Goods Administration site